Life expectancy crisis in the USA: The opioid crisis is not the decisive factor

March 17, 2020

Life expectancy in the USA is no longer rising. This stagnation has long been largely attributed to increasing numbers of drug deaths due to the opioid crisis. But Mikko Myrskylä and colleagues have now shown that deaths due to cardiovascular diseases are in fact having a much larger impact on life expectancy.

Over each decade of the past century, life expectancy in the USA rose by two years. This is no longer the case. Since 2010, life expectancy has not improved. Until now, this fact has mainly been attributed to the rising number of drug deaths due to the opioid crisis.

But Mikko Myrskylä, Director of the Max Planck Institute for Demographic Research in Rostock, together with Neil Mehta and Leah Abrams from University of Michigan have shown a stall in declining cardiovascular deaths is a more likely explanation for the end of stagnation of life expectancy. They have published their findings in the scientific journal PNAS.

Drug-related deaths have little influence on life expectancy

The remaining life expectancy of 25-year-old Americans would have risen by 1.1 years between 2010 and 2017 if deaths from cardiovascular diseases had declined as much over that period as they did between 2000 and 2009.

By contrast, the rising number of drug-related deaths had a much smaller influence on life expectancy. "If the number of drug-related deaths had remained constant after 2010, male life expectancy would have risen just 0.4 years, or by around five months," Mikko Myrskylä explained. Thus, over the long run, reducing the number of drug-related deaths will not be sufficient to ensure that life expectancy in the USA resumes its upward trajectory.
Original publication

Mehta, N., Abrams, L., Myrskylä, M.: U.S. Life Expectancy Stalls Due to Cardiovascular Disease, not Drug Deaths. PNAS. (2020), DOI:


Related Cardiovascular Diseases Articles from Brightsurf:

Graz researchers identify biomarker for cardiovascular diseases
The role of the enzyme dipeptidyl peptidase 3 in the blood pressure-regulating renin-angiotensin system was investigated in the inter-university cooperation project BioTechMed-Graz.

Glomerular diseases linked to higher risk of cardiovascular conditions
Adults with glomerular diseases have a 2.5-times higher risk of developing cardiovascular disease than individuals in the general population.

New insight into neovessel formation shows promise in future treatment of cardiovascular diseases
A new study by researchers at the University of Eastern Finland provides novel insight into the previously unknown effects of factors regulating blood vessel formation.

Research reveals cilia's role in cardiovascular functions and genetic diseases
Research from Chapman University discover ciliary extracellular-like vesicles (cELVs). Released by fluid-shear, cELVs act as nano-compartments within a cilium.

Stretching your legs may help prevent diseases such as heart diseases and diabetes
New research published today in The Journal of Physiology shows that 12 weeks of easy-to-administer passive stretching helps improve blood flow by making it easier for your arteries to dilate and decreasing their stiffness.

Framework on how to safely resume essential cardiovascular diagnostic and treatment care during the COVID-19 pandemic, from the AHA and 14 North American cardiovascular societies
The American Heart Association, together with 14 cardiovascular societies in North America, today issued joint guidance, 'Safe Reintroduction of Cardiovascular Services during the COVID-19 Pandemic: Guidance from North American Society Leadership,' to outline a systematic, phased approach to safely reintroducing cardiovascular procedures for diagnosis and treatment during the COVID-19 pandemic.

Cardiovascular impairment in COVID-19
Anti-inflammatory therapies should be used to treat COVID-19 patients that are at risk of, or have developed, cardiovascular problems, recommend leading cardiologists from Beijing, China, who have detailed the different ways that COVID-19 could trigger serious inflammatory-related cardiovascular issues in patients.

A talk with your GP may prevent cardiovascular disease
Having a general practitioner (GP) who is trained in motivational interviewing may reduce your risk of getting cardiovascular disease.

Serum irisin: Pathogenesis and clinical research in cardiovascular diseases
In a new publication from Cardiovascular Innovations and Applications; Lutfu Askin, Kader Eliz Uzel, Okan Tanriverdi and Serdar Turkmen from the Department of Cardiology, Adiyaman Education and Research Hospital, Adiyaman, Turkey consider serum irisin pathogenesis and clinical research in cardiovascular diseases.

Improving cardiovascular health of the most vulnerable
A two-year pilot project led by Rick Stouffer, MD, shows how the cardiovascular health of the most vulnerable patients can be improved with free medications.

Read More: Cardiovascular Diseases News and Cardiovascular Diseases Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to